Skip to main content
. 2017 Nov 1;67(1):85–97. doi: 10.2337/db17-0367

Figure 4.

Figure 4

ACKO mice are protected from HFD-induced metabolic disorders. A: Body weight of AKO (left, n = 9–10) and CKO (right, n = 9–17) mice and their respective controls (Ctrl) before and after 16 weeks of HFD feeding. B: Body weight curve of control and ACKO mice (n = 10–14) fed with HFD for 16 weeks. C: Tissue weight of control and ACKO mice (n = 10–14) fed with HFD for 16 weeks. D and E: Fasting blood glucose (D) and plasma insulin (E) concentrations in mice fed with HFD for 12 weeks (n = 10–14). F: GTT (left) and ITT (right) in mice fed with HFD for 20 weeks (n = 6). G: Immunoblots of total protein lysates from HFD-fed mice injected with saline or insulin (Ins, 1 unit kg−1) for 10 min. H: H&E staining of tissue sections. Scale bars, 200 μm. I: Liver TAG content in HFD-fed mice (n = 7–9). Data represent mean ± SEM. AUC, area under the curve; Quad, quadriceps muscle. *P < 0.05, **P < 0.01, ***P < 0.001.